InMed Pharmaceuticals Inc. (INM)
↓ Download CSV- Sector Manufacturing
- Incorporated A1
- Fiscal year ends Jun 30
In fiscal 2025, InMed Pharmaceuticals Inc. reported revenue of $4.94M, up 7.5% from the prior year. The company ran a net loss, with a net margin of -165.1% and a gross margin of 34.5%. It held $15.58M in total assets against $2.15M in total liabilities.
Key ratios (FY2025)
34.5%
Gross margin
-165.1%
Net margin
-60.8%
Return on equity
+7.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.94M | $4.60M | $4.14M | $1.09M | — | — | — |
| Cost of Revenue | $3.24M | $3.50M | $2.73M | $545.9K | — | — | — |
| Gross Profit | $1.71M | $1.10M | $1.40M | $543.5K | — | — | — |
| Operating Income | — | — | -$7.95M | -$18.60M | -$10.20M | — | — |
| Net Income | -$8.16M | -$7.68M | -$7.95M | -$18.60M | -$10.20M | -$8.94M | — |
| EPS (Diluted) | $-8.36 | $-20.14 | $-3.25 | $-33.17 | $-37.96 | — | — |
| Total Assets | $15.58M | $11.82M | $14.11M | $12.79M | $9.78M | $7.80M | — |
| Total Liabilities | $2.15M | $2.62M | $2.02M | $3.71M | $2.40M | $1.92M | — |
| Shareholders' Equity | $13.43M | $9.21M | $12.09M | $9.08M | $7.38M | $5.88M | $14.24M |
| Cash & Equivalents | $11.08M | $6.57M | $8.91M | $6.18M | $7.36M | $5.81M | $9.84M |
| Operating Cash Flow | -$7.77M | -$6.99M | -$7.28M | -$15.58M | -$9.79M | -$7.37M | — |
| Capital Expenditures | — | $9.3K | $160.0K | $39.1K | $1.7K | $42.6K | — |
| Shares Outstanding | 2.00M | 445.9K | 3.33M | 650.7K | 322.0K | 5.22M | — |